Skip to main content
. 2024 Jul 4;29(7):10.1111/adb.13421. doi: 10.1111/adb.13421

FIGURE 4.

FIGURE 4

Counteraction caused by the TRPV1 antagonist against attenuating effects of the CB1 antagonist on HDAC inhibitor‐ or CB1 agonist‐induced anxiolytic‐like behavioural alterations in the NC and/or IM treatment groups. The parameter values of the EPM test at the 2‐h time point after the last NC (0.8 mg/kg, sc) and/or IM (10 min) treatment are shown as means with SD bars (n = 10) for each anxiolytic‐like drug (HDAC inhibitor or CB1 agonist) plus CB1 antagonist cotreatment group with or without additional TRPV1 antagonist (with each ip dose [mg/kg]), and statistical significance in post hoc tests is denoted using the symbols as defined below. The detailed data and statistical results have been included in Table S4. (A) SB (100 mg/kg, ip) plus SR (1 mg/kg, ip) cotreatment groups with (or without) additional CZ (1 mg/kg, ip) (SB + SR + CZ groups); (B) VA (300 mg/kg, ip) plus SR (1 mg/kg, ip) cotreatment groups with (or without) additional CZ (1 mg/kg, ip) (VA + SR + CZ groups); (C) AC (0.2 mg/kg, ip) plus SR (1 mg/kg, ip) cotreatment groups with (or without) additional CZ (1 mg/kg, ip) (AC + SR + CZ groups). **P < 0.01: significant attenuation as compared with the control group; ++P < 0.01: significant increase as compared with the NC, IM, or NC‐IM group without any cotreatments; $$P < 0.01: significant attenuation as compared with the IM group without any cotreatments; ##P < 0.01: significant attenuation as compared with the NC, IM, or NC‐IM group cotreated with the efficacious (anxiolytic‐like) HDAC inhibitor or CB1 agonist; &&P < 0.01: significant increase as compared with the NC, IM, or NC‐IM group cotreated with the mitigating drug (HDAC inhibitor or CB1 agonist) plus SR.